The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis

References

• Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–1757.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–944.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.
   PubMed Web of Science ®Google Scholar
• Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255–1274.
   PubMed Web of Science ®Google Scholar
• Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193–205.
   PubMed Web of Science ®Google Scholar
• Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med. 2007;356:1364–1366.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933–1942.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy. J Thorac Disease. 2017;9:2308–2310.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Daida H, Ikewaki K, et al. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Atherosclerosis. 2017;261:69–77.
   PubMed Web of Science ®Google Scholar
• Bowman, Hopewell, Chen, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Shah S, Sapre A, et al. A multiregional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol. Am J Cardiol. 2017;120:569–576.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Klouras E, Barkas F, et al. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Rev Cardiovasc. 2016;14:953–962.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. London: The Cochrane Collboration; 2009.
   Google Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks J, et al. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Shah S, Kher U, et al. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol. Am J Cardiol. 2017;119:388–396.
   PubMed Web of Science ®Google Scholar
• Arai H, Teramoto T, Daida H, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2016;249:215–223.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Besseling J, Shah S, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385:2153–2161.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Shirakawa M, Kikuchi M, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia. Atherosclerosis. 2013;230:52–60.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415.
   PubMed Web of Science ®Google Scholar
• Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352–360.
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370:1907–1914.
   PubMed Web of Science ®Google Scholar
• Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains effcient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443–3454.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415.
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Kastelein JJ, Van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386:452–460.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Jama. 2011;306:2099–2109.
   PubMed Web of Science ®Google Scholar
• Inazu A. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234–1238.
   PubMed Web of Science ®Google Scholar
• Thompson A. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. Jama. 2008;299:2777–2788.
   PubMed Web of Science ®Google Scholar
• Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48:646–654.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Awan Z, Chretien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022–1036.
   PubMed Web of Science ®Google Scholar
• Urban D, Poss J, Bohm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62:1401–1408.
   PubMed Web of Science ®Google Scholar
• Li C, Lin L, Zhang W, et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc. 2015;4:001937.
   PubMed Web of Science ®Google Scholar
• van der Tuin SJ, Kühnast S, Berbée JF, et al. Anacetrapib reduces (V)LDL-cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res. 2015;56:2085–2093.
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Filippatos TD, Loukas T, et al. Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis. 2006;187:170–176.
   PubMed Web of Science ®Google Scholar
• Thomas T, Zhou H, Karmally W, et al. CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol. 2017;37:1770–1775.
   PubMed Web of Science ®Google Scholar
• Brown AL, Brown JM. Anacetrapib-driven triglyceride lowering explained: the fortuitous role of CETP in the intravascular catabolism of triglyceride-rich lipoproteins. J Lipid Res. 2017;58:1031–1032.
   PubMed Web of Science ®Google Scholar
• HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Filippas NS, Pappa E, et al. PCSK9 and carbohydrate metabolism: a double-edged sword. World J Diabetes. 2017;8:311–316.
   PubMed Web of Science ®Google Scholar
• Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. Jama. 2016;316:1383–1391.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye KA, Tardif JC, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011;124:555–562.
   PubMed Web of Science ®Google Scholar
• Claudio B, Arrigo FGC. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia. Expert Opin Drug Metab Toxicol. 2017;13:205–209.
   PubMed Web of Science ®Google Scholar
• Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther. 2008;84:679–683.
   PubMed Web of Science ®Google Scholar
• Kumar S, Tan EY, Hartmann G, et al. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos. 2010;38:474–483.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.
   PubMed Web of Science ®Google Scholar